Flaviviruses, such as Zika virus (ZIKV), Japanese encephalitis virus (JEV), Dengue virus (DENV), and West Nile virus (WNV), are important arthropod-borne pathogens that present an immense global health problem. Their unpredictable disease severity, unusual clinical features, and severe
neurological manifestations underscore an urgent need for
antiviral interventions.
Furin, a host
proprotein convertase, is a key contender in processing
flavivirus prM protein to M
protein, turning the inert virus to an infectious particle. For this reason, the current study was planned to evaluate the
antiviral activity of decanoyl-
Arg-Val-Lys-Arg-chloromethylketone, a specific
furin inhibitor, against flaviviruses, including ZIKV and JEV. Analysis of
viral proteins revealed a significant increase in the prM/E index of ZIKV or JEV in
dec-RVKR-cmk-treated Vero cells compared to
DMSO-treated control cells, indicating
dec-RVKR-cmk inhibits prM cleavage. Plaque assay, qRT-PCR, and immunofluorescence assay revealed a strong
antiviral activity of
dec-RVKR-cmk against ZIKV and JEV in terms of the reduction in virus progeny titer and in
viral RNA and
protein production in both mammalian cells and mosquito cells. Time-of-
drug addition assay revealed that the maximum reduction of virus titer was observed in post-
infection treatment. Furthermore, our results showed that
dec-RVKR-cmk exerts its inhibitory action on the virus release and next round infectivity but not on
viral RNA replication. Taken together, our study highlights an interesting
antiviral activity of
dec-RVKR-cmk against flaviviruses.